戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ith off-target effects, including nausea and gastrointestinal disturbance.
2 icities, peripheral neuropathy, fatigue, and gastrointestinal disturbances.
3  MMF for infection, myelosuppression, and/or gastrointestinal disturbances.
4  MMF for infection, myelosuppression, and/or gastrointestinal disturbances.
5 hrombotic episodes (7%), bone pain (5%), and gastrointestinal disturbance (4%).
6 most common drug-related adverse events were gastrointestinal disturbances and increased serum creati
7                                           As gastrointestinal disturbances are common in children wit
8 n in distal extremities including joints and gastrointestinal disturbances, but was absent from an as
9  anemia, 14%; and thrombocytopenia, 23%) and gastrointestinal disturbances (diarrhea, any grade, 72%;
10                                    Sleep and gastrointestinal disturbances have also been frequently
11 ers seeking medical care have a diagnosis of gastrointestinal disturbance in approximately one-third
12 he cause of chronic unexplained diarrhea and gastrointestinal disturbances in transplant patients.
13 ourse involved recurrent febrile illness and gastrointestinal disturbance, lacking an infective cause
14 effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities,
15 production (montelukast, n=6; placebo, n=2), gastrointestinal disturbance (montelukast, n=3; placebo,
16 protease inhibitors currently in use include gastrointestinal disturbances, paraesthesias, hyperbilir
17                               These included gastrointestinal disturbance (present in 9); edema (9);
18 imal performance included these factors plus gastrointestinal disturbance, severe neutropenia, and pr
19 such as bulbar dysfunction, hearing loss and gastrointestinal disturbance should help prioritize gene
20                          Ten trials reported gastrointestinal disturbances, such as nausea, vomiting,
21  frequent dosing schedules or elimination of gastrointestinal disturbances, the most common adverse e
22                                              Gastrointestinal disturbance was more common among patie
23               Sensorineural hearing loss and gastrointestinal disturbance were also important finding

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。